Get the Stockscreener App
1.99
2.05%
0.04
Pre-market:
2.00
0.01
+0.50%
Palisade Bio Inc stock is traded at $1.99, with a volume of 2.58M.
It is up +2.05% in the last 24 hours and down -4.33% over the past month.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
See More
Previous Close:
$1.95
Open:
$1.94
24h Volume:
2.58M
Relative Volume:
0.69
Market Cap:
$345.82M
Revenue:
$250.00K
Net Income/Loss:
$-16.78M
P/E Ratio:
-1.3402
EPS:
-1.4848
Net Cash Flow:
$-10.85M
1W Performance:
+9.94%
1M Performance:
-4.33%
6M Performance:
-10.76%
1Y Performance:
+146.59%
1-Day Range:
$1.94
$2.00
1-Week Range:
$1.82
$2.0675
52-Week Range:
$0.53
$2.855
Palisade Bio Inc Stock (PALI) Company Profile
Name
Palisade Bio Inc
Sector
Industry
Phone
(858) 704-4900
Address
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Compare PALI vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PALI
Palisade Bio Inc
|
1.99 | 338.87M | 250.00K | -16.78M | -10.85M | -1.4848 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Palisade Bio Inc Stock (PALI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Initiated | Wolfe Research | Outperform |
| Mar-26-26 | Initiated | H.C. Wainwright | Buy |
| Feb-25-26 | Initiated | Stifel | Buy |
| Jan-09-26 | Initiated | B. Riley Securities | Buy |
| Dec-29-25 | Initiated | Piper Sandler | Overweight |
Palisade Bio Inc Stock (PALI) Latest News
PALI Q1 2026 Earnings: EPS Misses Estimates as Palisade Bio Advances Pipeline EffortsGuidance Downgrade Alert - Newser
PALI Should I Buy - Intellectia AI
[EFFECT] PALISADE BIO, INC. SEC Filing - Stock Titan
Palisade Bio, Inc.Common Stock (NQ: PALI - FinancialContent
Palisade Bio Records Q1 Earnings and Advances Clinical Pipeline - HarianBasis.co
Palisade Bio (PALI) Reports Q1 2026 Results as R&D Expenses Rise to $6.4M - Yahoo Finance
Number of shareholders of Palisade Bio, Inc. – MUN:7NS0 - TradingView
10 Best NASDAQ Stocks Under $5 to Buy Right Now - Insider Monkey
RA Capital and partners disclose 9.99% stake in Palisade Bio (PALI) via warrants and shares - Stock Titan
[SCHEDULE 13G/A] PALISADE BIO, INC. Amended Passive Investment Disclosure - Stock Titan
Commodore Capital reports 12.37M-share stake in Palisade Bio (PALI) - Stock Titan
Perceptive Advisors (NASDAQ: PALI) reports a 7.9% collective stake in Palisade Bio - Stock Titan
Ameriprise/Columbia disclose 8.71M-share stake in Palisade Bio (NASDAQ: PALI) - Stock Titan
We're Not Worried About Palisade Bio's (NASDAQ:PALI) Cash Burn - Yahoo Finance
Analysts Are Bullish on These Healthcare Stocks: BridgeBio Pharma (BBIO), Palisade Bio (PALI) - The Globe and Mail
Palisade Bio Incmay offer and sell up to $300 million of securitiesSEC filing - marketscreener.com
Palisade Bio (NASDAQ: PALI) files $300M shelf to offer securities - Stock Titan
Palisade Bio Q1 net loss widens on higher R&D costs - TradingView
Palisade Bio (PALI) ramps PALI-2108 trials with $132.6M cash runway - Stock Titan
BRIEF-Palisade Bio Q1 EPS USD -0.05 - TradingView
Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108 - GlobeNewswire
Palisade Bio (NASDAQ: PALI) boosts R&D spend to advance PALI-2108 - Stock Titan
Palisade Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
TradingKey - TradingKey
Palisade Bio Inc expected to post a loss of 4 cents a shareEarnings Preview - TradingView
Palisade Bio (PALI) price target decreased by 12.09% to 10.20 - MSN
Palisade Bio, Inc. (NASDAQ:PALI) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Palisade Bio Data Supports Once-Daily Ulcerative Colitis Treatment Due to Sustained IC90 Coverage - geneonline.com
Palisade Bio presents pharmacokinetic data for ulcerative colitis drug By Investing.com - Investing.com South Africa
Palisade Bio presents pharmacokinetic data for ulcerative colitis drug - Investing.com
Palisade UC pill stayed above IC90 through the dosing interval - Stock Titan
MSN Money - MSN
Palisade Bio (PALI) Expected to Announce Earnings on Monday - MarketBeat
What Palisade Bio (PALI) capital allocation tells us | Q4 2025: Earnings Beat EstimatesExpert Momentum Signals - Newser
Major share increase and equity plan votes ahead for Palisade Bio (NASDAQ: PALI) - Stock Titan
Palisade Bio Participates in Virtual Investor "What This Means" Segment - 富途牛牛
Here's Why Palisade Bio (PALI) Could be Great Choice for a Bottom Fisher - MSN
PALI Palisade Bio posts narrower than expected Q4 2025 loss, shares gain more than four percent.Secondary Offering - Cổng thông tin điện tử tỉnh Lào Cai
12 Health Care Stocks Moving In Wednesday's Intraday SessionAxe Compute (NASDAQ:AGPU), Akanda (NASDAQ - Benzinga
Analysts Offer Predictions for Palisade Bio Q1 Earnings - MarketBeat
Brokers Issue Forecasts for Palisade Bio Q3 Earnings - MarketBeat
Palisade Bio (NASDAQ: PALI) asks shareholders to lift authorized shares to 450M - Stock Titan
Palisade Bio Inc Stock (PALI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):